TY - JOUR AU - Daly, Kieran AU - Huang, Laurence AU - Morris, Alison AU - Koch, Judy AU - Crothers, Kristina AU - Levin, Linda AU - Eiser, Shary AU - Satwah, Supriya AU - Zucchi, Patrizia AU - Walzer, Peter T1 - Antibody Response to Pneumocystis jirovecii T2 - Emerging Infectious Disease journal PY - 2006 VL - 12 IS - 8 SP - 1231 SN - 1080-6059 AB - We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the fragments measured by an ELISA were found in both groups. Serum antibodies to MsgC in P. jirovecii patients rose to a peak level 3–4 weeks (p<0.001) after recovery from pneumocystosis; baseline CD4+ count >50 cells/μL and first episode of pneumocystosis were the principal host factors associated with this rise (both p<0.001). Thus, MsgC shows promise as a serologic reagent and should be tested further in clinical and epidemiologic studies. KW - Human Immunodeficiency Virus (HIV) KW - Acquired Immune Deficiency Syndrome (AIDS) KW - Pneumocystis pneumonia KW - Pneumocystis jirovecii KW - Recombinant antigens KW - Major surface glycoprotein (Msg) KW - Serum antibody responses KW - Enzyme-linked immunosorbent assay (ELISA) KW - CD4+ cells KW - First episode pneumocystosis KW - United States DO - 10.3201/eid1208.060230 UR - https://wwwnc.cdc.gov/eid/article/12/8/06-0230_article ER - End of Reference